Uric acid therapy prevents early ischemic stroke progression: A tertiary analysis of the URICO-ICTUS trial (Efficacy Study of Combined Treatment With Uric Acid and r-tPA in Acute Ischemic Stroke)

Stroke

Volumn 47, Issue 11, 2016, Pages 2874-2876

  Amaro, Sergio ^a,b   Laredo, Carlos ^a,b   Renú, Arturo ^a,b   Llull, Laura ^a,b   Rudilosso, Salvatore ^a,b   Obach, Víctor ^a,b   Urra, Xabier ^a,b   Planas, Anna M ^c   Chamorro, Ángel ^a,b,d  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INST D INVESTIGACIONS B   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

antioxidant; clinical trials; ischemic stroke; neuroprotection; treatment

Indexed keywords

ALTEPLASE; PLACEBO; URIC ACID; ANTIOXIDANT; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; COLLATERAL CIRCULATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; EARLY ISCHEMIC STROKE WORSENING; FEMALE; GENERAL CONDITION DETERIORATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; STROKE;

ANTIOXIDANTS; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); STROKE; TISSUE PLASMINOGEN ACTIVATOR; URIC ACID;

EID: 84991510934     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.014672     Document Type: Article

References (15)

1. Chamorro A, Dirnagl U, Urra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016;15:869-881. doi: 10.1016/S1474-4422(16)00114-9.
2. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS, et al; Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke. 2005;36:1808-1813. doi: 10.1161/01.STR.0000173403.60553.27.
3. Toni D, Fiorelli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C, et al. Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. Arch Neurol. 1995;52:670-675.
4. Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Martí-Fábregas J, et al; URICO-ICTUS Investigators. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomized, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13:453-460.
5. Tan IY, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, et al. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol. 2009;30:525-531. doi: 10.3174/ajnr.A1408.
6. Leigh R, Zaidat OO, Suri MF, Lynch G, Sundararajan S, Sunshine JL, et al. Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. Stroke. 2004;35:1903-1907. doi: 10.1161/01.STR.0000132571.77987.4c.
7. Seners P, Turc G, Tisserand M, Legrand L, Labeyrie MA, Calvet D, et al. Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors. Stroke. 2014;45:2004-2009. doi: 10.1161/STROKEAHA.114.005426.
8. Vila N, Castillo J, Dávalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671-675. doi: 10.1161/01. STR.0000057976.53301.69.
9. Serena J, Rodríguez-Yáñez M, Castellanos M. Deterioration in acute ischemic stroke as the target for neuroprotection. Cerebrovasc Dis. 2006;21(suppl 2):80-88. doi: 10.1159/000091707.
10. Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015;86:87-94. doi: 10.1136/jnnp-2014-308327.
11. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431-1568.
12. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-And radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858-6862.
13. Amaro S, Planas AM, Chamorro A. Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neurother. 2008;8:259-270. doi: 10.1586/14737175.8.2.259.
14. Onetti Y, Dantas AP, Perez B, Cugota R, Chamorro A, Planas AM, et al. Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: a target of uric acid treatment. Am J Physiol Heart Circ Physiol. 2015;308:H862-H874. doi: 10.1152/ajpheart.00001.2015.
15. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2007;27:14-20. doi: 10.1038/sj.jcbfm.9600312.